Tracers / [18F]JK-PSMA-7
[18F]JK-PSMA-7
Also written as (((S)-1-carboxy-5-(6-([18F]fluoro)-2-methoxynicotinamido)pentyl)carbamoyl)-L-glutamic acid; [18F]JK-PSMA-7; [18F]JK-PSMA7; [F-18]JK-PSMA-7; [F-18]JK-PSMA7
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 5
What it is
- Compound class
- Urea-based PSMA-targeting small molecule (Lys-urea-Glu inhibitor)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) inhibitor PMID 34370181
- Clinical application
- PET imaging of PSMA expression in prostate cancer and investigational use in soft tissue sarcoma PMID 39861180
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| AllinOne (AiO) Trasis | vendor cassette | HPLC+SPE | 58% no | >99% | 5-(((S)-6-(tert-butoxy)-5-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-6-oxohexyl)carbamoyl)-6-methoxy-N,N,N-trimethylpyridin-2-ammonium triflate (5) Trasis | 39861180 2025 Pharmaceuticals (Basel) the versatile cassette-based Trasis AllinOne (AIO) synthesizer — The total activity yield of [18F]JK-PSMA-7 ([18F]4) obtained using the AIO system was 38.9 ± 4.0% (n = 260; radiochemical yield of 58%) |
| — | — | — | — | — | — | 41886137 2026 Curr Treat Options Oncol |
| — | — | — | — | — | — | 40146266 2025 Eur J Nucl Med Mol Imaging |
| Manual synthesis | — | — | — | — | — | 34370181 2022 Mol Imaging Biol [68Ga]Ga-PSMA-11 and [18F]F-JK-PSMA-7 were labeled according to standard protocols, which have been published elsewhere [18]. |
| — | — | — | — | — | — | 33398412 2021 Eur J Nucl Med Mol Imaging |
Need this precursor?We can point you to suppliers for [18F]JK-PSMA-7, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]JK-PSMA-7.
Get in touchNotes
Added from reverse module search (stage 6); 5 article(s) with F-18. | Stage 28: added indication(s) onc-sarcoma from consolidated missing-rubric review.